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Effect on health- related quality of life of 
the X- Bolt dynamic plating system versus 
the sliding hip screw for the fixation of 
trochanteric fractures of the hip in adults: the 
WHiTE Four randomized clinical trial
Aims
Surgical treatment of hip fracture is challenging; the bone is porotic and fixation failure 
can be catastrophic. Novel implants are available which may yield superior clinical out-
comes. This study compared the clinical effectiveness of the novel X- Bolt Hip System 
(XHS) with the sliding hip screw (SHS) for the treatment of fragility hip fractures.
Methods
We conducted a multicentre, superiority, randomized controlled trial. patients aged 60 
years and older with a trochanteric hip fracture were recruited in ten acute UK NHS 
hospitals. Participants were randomly allocated to fixation of their fracture with XHS or 
SHS. A total of 1,128 participants were randomized with 564 participants allocated to 
each group. participants and outcome assessors were blind to treatment allocation. The 
primary outcome was the EuroQol five- dimension five- level health status (EQ- 5D- 5L) 
utility at four months. The minimum clinically important difference in utility was pre- 
specified at 0.075. Secondary outcomes were EQ- 5D- 5L utility at 12 months, mortality, 
residential status, mobility, revision surgery, and radiological measures.
Results
Overall, 437 and 443 participants were analyzed in the primary intention- to- treat  
analysis in XHS and SHS treatment groups respectively. There was a mean difference of 
0.029 in adjusted utility index in favour of XHS with no evidence of a difference between 
treatment groups (95% confidence interval -0.013 to 0.070; p = 0.175). There was no evi-
dence of any differences between treatment groups in any of the secondary outcomes. The 
pattern and overall risk of adverse events associated with both treatments was similar.
Conclusion
Any difference in four- month health- related quality of life between the XHS and SHS is 
small and not clinically important. There was no evidence of a difference in the safety 
profile of the two treatments; both were associated with lower risks of revision surgery 
than previously reported.
Cite this article: Bone Joint J 2021;103-B(2):256–263.
introduction
Hip fractures are one of the greatest challenges 
facing the medical community. In 2000, there 
was an estimated global incidence of nine million 
osteoporotic fractures, of which 1.6 million were 
hip fractures.1 These fractures constitute a heavy 
socioeconomic burden worldwide. The cost of 
this clinical problem is estimated at 5.8 million 
disability adjusted life years lost, 1.75% of the 
total healthcare burden in established market 
economies.1
Approximately half of all hip fractures lie outside 
of the joint capsule and the great majority of these 
are trochanteric fractures—those in the region 
.
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Fig. 1
Anteroposterior radiograph of sliding hip screw fixation of a right 
trochanteric fracture.
Fig. 2
Anteroposterior radiograph of X- Bolt Dynamic Hip Plating System 
fixation of a right trochanteric fracture.
between the greater and lesser trochanter that can be typically 
treated with fixation rather than replacement.2
The sliding hip screw (SHS) is well established in the treatment 
of these fractures and in many patients is effective at allowing 
controlled collapse of the fracture with consequent mechanical 
stability leading to successful bone healing (Figure 1).3 However, 
in some people fixation strength is compromised due to porotic 
cancellous bone, making fixation difficult, risking implant cut out, 
when there is insufficient bone at the fracture to share the load on 
the limb with the fixation device. Rather than controlled collapse 
along the line of the screw, the screw may cut out from the hip 
leading to failure of the fixation and damage to the hip joint.4 
Revision surgery, to either re- fix or replace the hip, is complex 
and the outcomes are very poor in this frail group of patients with 
inpatient mortality approaching 50%.4
The X- Bolt Dynamic Hip Plating System (XHS; X- Bolt, 
Dublin, Ireland) builds on the successful design features of the 
SHS; it only differs importantly in the nature of the fixation in the 
head of the femur. Expanding flanges are deployed to engage and 
compress the surrounding cancellous bone improving fixation in 
cadaveric and biomechanical studies (Figure 2).5 Biomechanical 
testing has demonstrated that the XHS has improved cut out 
strength compared with the SHS, the principal means of implant 
failure in the treatment of these fractures.6 There is also improved 
rotational control and better torsional stability at the fracture 
site.7 Our randomized pilot study, Warwick Hip Trauma Evalu-
ation (WHiTE) One, has indicated that there is a trend towards 
a reduced risk of revision using the XHS compared with the 
SHS.8 The aim of this trial was to quantify the comparative clin-
ical effectiveness of the XHS and the SHS for the treatment of 
fragility hip fractures.9
Methods
Trial design summary. This was a multicentre, multi- surgeon, 
two- arm, parallel- group randomized controlled trial. Full de-
tails of the protocol have been published previously.9 The West 
Midlands NHS Research Ethic Committee gave ethical approv-
al on 5 February 2016 (WM/16/0001).
Eligibility. Patients were screened in ten acute NHS hospitals in 
the UK. Patients were included who presented with trochanteric 
fracture of the hip, determined by the treating surgeon using 
the AO/OTA classifcation,10 and who in their opinion would 
benefit from SHS fixation. Patients were excluded who: were 
younger than 60 years of age; had a sub- trochanteric fracture; 
or who were managed nonoperatively. Overall, 2,105 patients 
were potentially eligible for entry into the trial between June 
2016 and April 2018 at the ten study sites (Figure 3). Overall, 
1,128 were randomized and consented into the trial. Twelve 
participants were randomized in error; of whom eight had the 
wrong type of fracture and received a non- trial intervention, and 
four were randomized twice. Three participants (XHS = 2, SHS 
= 1) withdrew immediately post- randomization for whom no 
data are available. Baseline demographic data were similar in 
both treatment groups (Table I). Participants had a median age 
of 86 (IQR 79 to 91) years, 825 participants were female and 
pre- injury median EuroQol Five- dimension Health Status and 
Index (EQ- 5D) utility index was approximately 0.7 (0.4 to 0.8).
Standardized treatment pathway. Diagnosis of a hip fracture 
was confirmed as per routine clinical care. Routine investiga-
tions, anaesthetic assessment, antibiotic, and venous thrombo-
prophylaxis were used as per local policy.
Anaesthesia was achieved in accordance with local policies. 
Perioperative analgesia was achieved by combining a local 
anaesthetic nerve block, periarticular anaesthetic infiltration, 
intravenous paracetamol 1 g intravenous infusion, and opiate 
analgesia as clinically indicated.
Internal fixation with either device was performed following 
the manufacturer’s guidelines; the positioning of the participant, 
surgical approach, and wound closure was determined by the 
operating surgeon. Postoperative analgesia was prescribed by 
the responsible clinical teams as appropriate. In the postopera-
tive period, as per standard of care, participants in both groups 
underwent an initial physiotherapy and occupational therapy 
assessment. An initial treatment plan was devised, aiming to 
mobilize participants through early, active, full weight- bearing. 
Participants were discharged from the acute Orthopaedic 
Trauma Ward at the earliest safe opportunity to the most appro-
priate discharge destination.
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Assessed as eligible (n = 2,105)
Randomized (n = 1,140)
Randomized in error (n = 4)Randomized in error (n = 8)
Allocated to XHS (n = 564)
- Received XHS* (n = 476)
- Did not receive XHS (n = 63)
 - Received SHS (n = 55)
 - Received other treatment (n = 8)
 - No operation performect† (n = 2)
- Treatment unknown (n = 25)
 - Withdrew before data collection‡ (n = 23)
 - Withdrew all consent from trial§ (n = 2)
Allocated to SHS (n = 564)
- Received SHS* (n = 527)
- Did not receive SHS (n = 7)
 - Received XHS (n = 0)
 - Received other treatment (n = 5)
 - No operation performed (n = 2)
- Treatment unknown (n = 30)
 - Withdrew before data collection‡ (n = 29)
 - Withdrew all consent from trial¶ (n = 1)
XHS (n = 564)
Baseline EQ-5D-5L
- Completed (n = 403) | Missing** (n = 108)
- Withdrawn before baseline‡§ (n = 25)
- Died before baseline (n = 28)
4-mth EQ-5D-5L
- Completed (n = 324) | Missing** (n = 92)
- Withdrawn before 4-mth§†† (n = 35)
- Died before 4-mth‡‡ (n = 113)
12-mth EQ-5D-5L
- Completed (n = 277) | Missing** (n = 86)
- Withdrawn before 12-mth§†† (n = 43)
- Died before 12-mth‡‡ (n = 158)
SHS (n = 564)
Baseline EQ-5D-SL
 - Completed (n = 403) | Missing** (n = 92)
 - Withdrawn before baseline‡¶ (n = 42)
 - Died before baseline (n = 27)
4-mth EQ-5D-SL
 - Completed (n = 318) | Missing** (n = 66)
 - Withdrawn before 4-mth¶†† (n = 55)
 - Died before 4-mth‡‡ (n = 125)
12-mth EQ-5D-SL
 - Completed (n = 273) | Missing** (n = 62)
 - Withdrawn before 12-mth¶†† (n = 61)
 - Died before 12-mth‡‡ (n = 168)
Not recruited (n = 965)
 - Declined to participate (n = 77)
 - Missed (n = 888)
Fig. 3
CONSORT flow diagram. *Derived using operative data; †Participants died before operation performed; ‡Where patients withdrew before baseline 
data collection, hospital information and operative details will not have been collected; §Includes two participants who received treatment but 
subsequently withdrew and removed all consent for data to be used in trial; ¶Includes one participant who received treatment but subsequently 
withdrew and removed all consent for data to be used in trial; **Includes participants who did not complete this information on their questionnaire, 
who have consented to routine data collection only, or who have not returned their questionnaire; ††Includes all participants who have withdrawn 
prior to this timepoint; ‡‡Includes all participants who have died prior to this timepoint.
Allocated treatments. Participants were randomly allocated to 
one of two groups: SHS or XHS. The allocation sequence was 
generated with a 1:1 ratio using randomly permuted blocks 
of varying size by the trial statistician, stratified by trial centre. 
Allocations were assigned using secure, online randomization 
via a distant computer- generated system administered by Oxford 
Clinical Trials Research Unit, University of Oxford. Participants 
were enrolled by a member of the site research staff and were as-
signed to their treatment allocation before surgery.
SHS. Fixation was with a SHS and standard lag screw. Briefly, 
the fracture was reduced by closed means under image intensi-
fier guidance. A wire was passed from the side of the femur into 
the centre of femoral head and then a channel opened to allow 
the passing of a large diameter cannulated screw over the wire 
and across the fracture. The screw was then mounted into a barrel 
attached to a side plate of a length determined by the operating 
surgeon. The use of any supplementary fixation such as wires, 
cables, lag screws, and trochanteric stablization plate attachments 
was permitted at the surgeon’s discretion.
XHS. Fixation was with an XHS, a very similar device to the SHS 
with side plate, barrel, and lag screw but equipped with an ex-
panding bolt to gain fixation within the femoral head. Similar to 
the SHS group, the fracture was reduced closed under fluoroscop-
ic guidance, a wire was passed across the fracture into the centre 
of femoral head and a channel opened with a reamer over the wire. 
The wire was then removed to allow the passing of the narrower 
but solid X- Bolt implant with associated flanges. The X- Bolt was 
then mounted into a barrel attached to a side plate of a length de-
termined by the operating surgeon. The use of any supplementary 
fixation such as wires, cables, lag screws, and trochanteric stabli-
zation plate attachments was permitted at the surgeon’s discretion.
Consent. It is recognized that patients with a hip fracture are 
a clinical priority for urgent operative care,11 with a preference 
to be treated on the next available trauma operating list. Most 
VOL. 103-B, No. 2, FEBRUARY 2021
X- BOLT DYNAMIC PLATING SYSTEM VERSUS THE SLIDING HIP SCREW FOR THE FIXATION OF TROCHANTERIC FRACTURES 259






Median age, yrs (IQR) 85.8 (80.3 to 90.6) 85.6 (78.8 to 90.9)
Female sex, n (%) 401 (71.4) 424 (75.3)
Diabetic, n (%)† 69 (16.0) 78 (18.0)
Smoker, n (%)‡ 40 (9.5) 48 (11.2)
Weekly alcohol consumption, n 
(%)§
421 (74.9) 423 (75.1)
0 to 7 units 373 (88.6) 371 (87.7)
8 to 14 units 24 (5.7) 20 (4.7)
15 to 21 units 11 (2.6) 13 (3.1)
> 21 units 13 (3.1) 19 (4.9)
pre- fracture mobility, n (%)¶ 540 (96.1) 534 (94.8)
Freely mobile without aids 197 (36.5) 186 (34.8)
Mobile outdoors with one aid 111 (20.6) 99 (18.5)
Mobile outdoors with two aids or 
frame
98 (18.1) 102 (19.1)
Some indoor mobility but never 
goes outside without help
120 (22.2) 134 (25.1)
No functional mobility (using lower 
limbs)
5 (0.9) 8 (1.5)
Unknown 9 (1.7) 5 (0.9)
Residential status, n (%)** 315 (56.0) 335 (59.5)
Own home/sheltered housing 247 (78.4) 260 (77.6)
Residential care 41 (13.0) 46 (13.7)
Nursing care 21 (6.7) 25 (7.5)
Rehab unit (hospital bed in current 
trust)
1 (0.3) 1 (0.3)
Rehab (hospital bed in another 
trust)
1 (0.3) 0 (0)
Rehab (NHS- funded care home 
bed)
0 (0) 1 (0.3)
Acute hospital 4 (1.3) 2 (0.6)
Median preoperative AMTS (IQR)†† 8 (3 to 10) 8 (4 to 10)
Median pre- injury EQ- 5D- 5L (IQR)‡‡0.7 (0.4 to 0.8) 0.7 (0.4 to 0.8)
Median pre- injury EQ- 5D- 5L VAS 
(IQR)§§
70 (50 to 80) 70 (50 to 80)
AO/OTA fracture type, n (%)¶¶ 539 (95.9) 532 (94.5)
31A1 222 (41.2) 204 (38.3)
31A2 303 (56.2) 307 (57.7)
31A3 14 (2.6) 21 (3.9)
*Does not include three participants who withdrew under “No data, no 
contact” (X- Bolt XHS = 2, SHS = 1).
†Diabetes data not available for 131 XHS participants and 129 SHS 
participants.
‡Smoking data not available for 140 XHS participants and 136 SHS 
participants.
§Alcohol consumption data not available for 141 XHS participants and 
140 SHS participants.
¶Pre- fracture mobility data not available for 22 XHS participants and 29 
SHS participants.
**Residential status data not available for 247 XHS participants and 
228 SHS participants.
††Retrospective preoperative AMTS data not available for 31 XHS 
participants and 39 SHS participants.
‡‡Retrospective pre- injury EQ- 5D- 5L score not available for 161 XHS 
participants and 161 SHS participants.
§§Retrospective pre- injury EQ- 5D- 5L VAS not available for 161 XHS 
participants and 162 SHS participants.
¶¶Fracture type data not available for 23 XHS participants and 31 SHS 
participants.
AMTS, abbreviated mental test score; EQ- 5D- 5L, EuroQol five- 
dimension five- level questionnaire; IQR, interquartile range; SHS, 
sliding hip screw; VAS, visual analogue scale; XHS, X- Bolt hip system.
patients with a hip fracture are in pain and receive opiate anal-
gesia. Accordingly for many patients the initial period in hospital 
is confusing and disorientating. Similarly, patients’ next of kin, 
carers, and friends are often anxious at this time and may have 
difficulty in assimilating large amounts of information that they 
are given about the injury and plan for treatment. The initial focus 
is on obtaining consent for surgery, where possible, and informing 
the patient and any next of kin about immediate clinical care. It is 
often not possible for the patient or relative/carer (consultee) to 
review trial documentation, consider the information, and com-
municate an informed decision about whether they would wish 
to participate. The consent procedure for this trial reflected that of 
the surgery, with the clinical team assessing capacity before taking 
consent for the surgical procedure. This capacity assessment was 
then used to decide on the proper approach to consenting to the 
research study. An appropriate method, in line with the Mental 
Capacity Act 2005, was then used to gain either prospective or 
retrospective consent from the participant, or appropriate consult-
ee, by a Good Clinical Practice- trained,12 appropriately delegated 
member of the local research team.
Objectives. The primary objective of the trial was to quantify 
and draw inferences on the observed differences in partici-
pants’ health status between the trial treatment groups at four 
months post- surgery.
Secondary objectives were to quantify and draw inferences on 
the observed differences in: participants’ health status between 
the trial treatment groups at 12 months post- surgery; partici-
pants’ mortality within the first year post- surgery between the 
trial treatment groups; participants’ functional status between 
the trial treatment groups at 12 months post- surgery; partici-
pants’ residential status between the trial treatment groups at 
12 months post- surgery; the risks of revision surgery within the 
first year post- surgery between the trial treatment groups; and 
the risk and distribution of complications within the first year 
post- surgery between the trial treatment groups.
Outcomes. The primary outcome was at four months post- 
surgery with longer- term follow- up at 12 months post- surgery. 
Outcome data were collected through questionnaires and review 
of the medical record; participant questionnaires were completed 
face- to- face at baseline and over the telephone by a member of the 
trial team or via post at both four and 12 months follow- up.
primary outcome measure. The primary outcome measure was 
health- related quality of life (HRQoL) at four months. The EuroQol 
Five- dimension Health Status and Index (EQ- 5D) is a validated 
measure of HRQoL, consisting of a five dimension health status 
classification system and a separate visual analogue scale.13 An up-
dated version of the EQ- 5D with five response levels (EQ- 5D- 5L) 
has recently been developed to enhance the responsiveness of the 
instrument to changes in patient health. The measurement properties 
of the EQ- 5D in this patient population have been extensively inves-
tigated and is currently the best measurement tool available.14,15 This 
outcome was obtained through telephone interview with the partici-
pant or consultee. EQ- 5D- 5L index values were derived by mapping 
EQ- 5D- 5L descriptive system data onto the EQ- 5D- 3L valuation set 
using the Crosswalk Index Value Calculator.16 Using this value set 
the scale ranges from -0.594, indicating the worse possible heath 
state, to 1.0, and is anchored at 0 and 1.0 indicating a health state 
equivalent death and perfect health respectively.
Follow us @BoneJointJ
X. L. GRIFFIN, J. ACHTEN, H. M. O’CONNOR, J. A. COOK, M. L. COSTA260
THE BONE & JOINT JOURNAL 





Surgery received, n (%)† 539 (95.9) 534 (94.8)
X- Bolt XHS 476 (88.3) 0 (0)
SHS 55 (10.2) 527 (98.7)
Received other treatment 8 (1.5) 5 (0.9)
No operation performed 0 (0) 2 (0.4)
Additional fixations, n (%)‡ 546 (97.2) 552 (98.0)
Screws 49 (9.0) 38 (6.9)
Wires 3 (0.5) 5 (0.9)
Trochanteric plates 15 (2.7) 23 (4.2)
None§ 479 (87.7) 486 (88.0)
Grade of operating surgeon, n (%)¶ 539 (95.9) 532 (94.5)
Consultant 196 (36.4) 172 (32.3)
SAS 22 (4.1) 22 (4.1)
ST3+ 282 (52.3) 304 (57.1)
Below ST3 22 (4.1) 22 (4.1)
Associate specialist 0 (0) 2 (0.4)
Staff grade/Speciality doctor 3 (0.6) 0 (0)
Unknown 14 (2.6) 10 (1.9)
*Does not include three participants who withdrew under “No data, no 
contact” (X- Bolt XHS = 2, SHS = 1).
†Surgery received data not available for 23 XHS participants and 29 
SHS participants.
‡Additional fixations data not available for 16 XHS participants and 9 
SHS participants.
§Includes participants where “None” was selected and where “No” 
has been recorded against each additional fixation option (XHS = 7; 
SHS = 14); this includes two SHS participants who did not have an 
operation performed and one XHS participant missing information on 
operation performed.
¶Surgeon grade information not available for 23 XHS participants and 
31 SHS participants.
SHS, sliding hip screw; XHS, X- Bolt hip system.
Secondary outcome measures. HRQoL was also similarly 
measured at 12 months using the EQ- 5D- 5L. Mortality was ob-
tained from participant’s medical notes, information from carers, 
and the NHS Digital Spine, an information technology infrastruc-
ture linking widely used healthcare IT systems.17
Functional status was assessed on an ordinal scale: freely 
mobile without aids; mobile outdoors with one aid; mobile 
outdoors with two aids or a frame; some indoor mobility but 
never goes outside without help; and no functional mobility 
(using lower limbs). Data were obtained prospectively through 
participant and carer telephone interviews.
Residential status was assessed on an ordinal scale: own home/
sheltered housing; residential care; nursing care; rehabilitation unit – 
hospital bed in the current trust; rehabilitation unit – hospital bed in 
another trust; rehabilitation unit – NHS- funded care home bed; and 
acute hospital. Data were obtained prospectively through participant 
and carer telephone interviews.
All- cause revision surgery was obtained from participant’s 
medical notes, participant and carer telephone interviews, and 
review of the index hospital digital medical imaging record. Compli-
cations were obtained from the participant’s medical notes and 
participant and carer telephone interviews. Radiological outcomes 
were collected from any radiographs taken as part of routine clinical 
follow- up during the first 12 months post- surgery, as planned in the 
protocol, but will be reported elsewhere.
Sample size. The best available evidence we had from data col-
lected during the WHiT (Warwick Hip Trauma) and WHiTE stud-
ies suggests that the SD for EQ- 5D at four months post- surgery is 
approximately 0.3 points.14 The best available evidence for what 
constitutes a minimal clinically important difference for EQ- 5D, 
which is important to detect, was estimated to be 0.075.18 Using a 
conservative estimate of the SD (0.33), this suggested a standard-
ized effect size of approximately 0.24; a ‘small to moderate effect’ 
based on Cohen’s criteria.19
Assuming that the EQ- 5D derived utility at four months post- 
surgery would have an approximate normal distribution, which 
was reasonable,14 and a 1:1 allocation ratio, then if the true 
difference between the experimental and control group EQ- 5D 
means was 0.075, for 90% power, we required 338 participants 
in both the experimental group and in the control group. Based 
upon a similar trial in this population we expected considerable 
loss to follow- up, due to death, increasing frailty and cognitive 
decline, and post- randomization withdrawals in participants 
who declined ongoing follow- up, so we assumed that only 
60% of recruited study participants would be available at the 
definitive outcome at four months.20 Conservatively, we aimed 
to recruit 1,128 patients to ensure 90% statistical power based 
upon these assumptions.
Blinding. In order to negate bias in the self- reported HRQoL 
outcome measures, participants were blinded to the treatment 
allocation; other outcomes were assessed by blinded research 
associates. The operating surgeon could not be blinded to the 
allocation, but took no part in the assessment of the trial out-
comes. Participants were kept blinded until the completion of 
the trial when the blind was broken. There was no formal anal-
ysis of the success of the blinding.
Statistical analysis. Descriptive analyses of participants’ baseline 
characteristics and intervention were summarized as means and 
SDs for normally distributed variables, as medians and interquartile 
ranges (IQRs) for non- normally distributed continuous variables, 
and as frequencies and percentages for binary and categorical varia-
bles. The main analyses of the primary and secondary outcome vari-
ables were conducted on an intention- to- treat (ITT) basis; including 
all participants with consent to use their data in their randomized 
groups, with no imputation for missing data.
Multivariate linear regression was used to investigate the primary 
outcome. The model included four- month EQ- 5D- 5L score as the 
dependent variable and treatment group as the main independent 
variable adjusted for centre, age, sex, and cognitive impairment at 
baseline. A zero value was imputed for the EQ- 5D Index for all those 
participants who had died prior to the collection timepoint; this is 
the recommended approach based upon empirical studies exploring 
options for handling death in these analyses.21 Cognitive impairment 
was assessed using the Abbreviated Mental Test Score (AMTS) and 
dichotomized by defining an AMTS of 7 or less as abnormal cogni-
tion and 8 or more as normal cognition.22 The model was replicated 
for EQ- 5D- 5L scores reported at 12 months post- surgery to assess 
for longer- term differences between treatment groups.
A generalized linear model (GLM) approach was used to analyze 
secondary outcomes. Mortality and all- cause revision surgery were 
analyzed with logistic regression, and functional status was analyzed 
with ordinal regression.23 The number and proportion of participants 
reporting each type of complication one or more times over the 12 
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Table iii. Results from multivariate regression for primary and secondary outcomes by allocated treatment.
Outcome XHS SHS Treatment effect
EQ- 5D Index n Mean score (SD) n Mean score (SD) Adjusted difference (95% Ci) * p- value
4 month EQ- 5D- 5L † 437 0.345 (0.355) 443 0.320 (0.359) 0.029 (-0.013 to 0.070) 0.175
12 month EQ- 5D- 5L 435 0.312 (0.364) 441 0.293 (0.361) 0.026 (-0.016 to 0.068) 0.232
Secondary outcomes n Events, n (%) n Events, n (%) Adjusted OR (95% Ci) * p- value
Mortality 454 161 (35.0) 456 170 (37.0) 0.873 (0.647 to 1.176) 0.371
All- cause revision 
surgery
522 14 (2.7) 502 11 (2.2) 1.260 (0.563 to 2.820) 0.573
n Median (iQR) n Median (iQR) Adjusted OR (95% Ci) * p- value
Functional status 327 3 (2 to 4) 320 3 (2 to 4) 0.991 (0.748 to 1.313) 0.952
n Median no. events (iQR) n Median no. events (iQR) Adjusted iRR (95% Ci) * p- value
Complications 470 0 (0 to 1) 470 0 (0 to 1) 0.936 (0.784 to 1.117) 0.461
*Primary model including EQ- 5D index, treatment, centre, age, sex, and cognitive impairment with SHS as the reference treatment group.
†Primary outcome.
CI, confidence interval; EQ- 5D- 5L, EuroQol five- dimension five- level questionnaire; IQR, interquartile range; OR, odds ratio; SHS, sliding hip screw; 
XHS, X- Bolt hip system.
Table iV. Reasons for all- cause revision surgery by treatment received.
Reason, n (%) X- Bolt XHS (n = 401) SHS (n = 493)
All cause revision 11 (2.7) 13 (2.6)
Failure of fixation 7 (1.7) 9 (1.8)
  Excess femoral neck collapse   2 (0.5)   2 (0.4)
  Femoral head cut- out   4 (1.0)   5 (1.0)
  Plate failure   1 (0.2)   2 (0.4)
Periprosthetic fracture 3 (0.7) 2 (0.4)
Revision malreduction 0 (0) 1 (0.2)
Infection 1 (0.2) 1 (0.2)
*One participant who underwent revision surgery did not receive 
either trial treatment so is excluded from this total; data may not match 
other tables.
SHS, sliding hip screw; XHS, X- Bolt hip system.
month follow- up period were explored and the count of the number 
of types of complications reported by each participant was analyzed 
using Poisson regression. As per the primary outcome, the regres-
sion models for the corresponding secondary outcomes included 
treatment as the main independent variable, adjusting for centre, 
age, sex, and cognitive impairment.
Radiological outcomes will be presented in a descriptive analysis 
elsewhere. Due to unexpectedly high volumes of missing data, resi-
dential status was also considered unsuitable for statistical analysis 
and only descriptive baseline data have been presented.
The sensitivity of the primary outcome analysis to assumptions 
made was assessed. The health state of participants prior to entry into 
the trial was accounted for by extending the main analysis to further 
adjust for retrospective baseline EQ- 5D- 5L score. The impact of 
the analysis population was evaluated using a per- protocol analysis, 
where participants who did not receive the treatment allocated to 
them were excluded, and Complier Average Casual Effect (CACE) 
analysis, where the adherence to treatment allocated is accounted for 
without exclusion. The imputation of zero for the EQ- 5D- 5L index 
values of participants who had died was investigated by repeating 
analyses solely among living participants. To ensure that any skew 
in the EQ- 5D- 5L data was not impacting the outcome, bootstrap-
ping using normal approximation and 10,000 iterations was adopted 
to estimate the confidence intervals (CIs) for the treatment effect. 
Finally, the sensitivity to departures from the missing at random 
assumption was evaluated using a pattern- mixture model, in which 
data and missingness are modelled jointly.
Treatment effects were summarized using 95% CIs along-
side a prespecified two- sided 5% significance level. Analyses 
were conducted using Stata v. 15.1 (StataCorp, College Station, 
Texas, USA).
Results
Data on the type of surgery received were available for 95% of partic-
ipants (1,073/1,128; Table II). A total of 55 participants allocated to 
XHS received SHS (10%); there were no crossovers from SHS to 
XHS. The reasons for crossover were surgeon choice (20), clinical 
decisions (9), fracture characteristics (8), implant and equipment 
issues (11), and unknown (7). Of the participants, 15 received treat-
ments not described in the protocol, for example an intramedullary 
nail, and 998 participants were operated on by a surgeon who was 
consultant or senior trainee grade.
Including participants who died, EQ- 5D- 5L data were avail-
able for analysis for 78% of participants at both the primary end- 
point (four months; 880/1,128) and longer- term follow- up (12 
months; 876/1,128) (Table III). There was no evidence of a differ-
ence between treatment groups in mean EQ- 5D index for either 
the primary outcome (adjusted difference 0.029; 95% CI -0.013 
to 0.070; XHS mean 0.345 (SD 0.355); SHS mean 0.320 (SD 
0.359)). The 12- month outcome result was similar with adjusted 
difference 0.026 (95% CI -0.016 to 0.068; XHS mean 0.312 (SD 
0.364); SHS mean 0.293 (SD 0.361)). A full breakdown of the 
responses provided to each domain of the EQ- 5D- 5L are reported 
in the Supplementary Material (Supplementary Tables i to iii). The 
longitudinal changes were similar between the treatment groups.
Pre- specified sensitivity analyses, including a per- protocol 
analysis and a CACE analysis, supported the findings of the 
primary analysis (Supplementary Table iv anf Figure a) and 
produced adjusted treatment effects consistent with that of the 
ITT analysis. Excluding participants who died increased the abso-
lute EQ- 5D index in both groups, reduced precision of the esti-
mate, and remained non- significant. Pattern- mixture modelling 
demonstrated that the modelled treatment effect was not sensitive 
to missing data either at the primary outcome timepoint (Supple-
mentary Figure b) or for the 12 months outcome (Supplementary 
Figure c).
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Functional status data were available for 57% of participants 
(647/1,128) with the median score for both groups of 3 (IQR2 
to 4), representing being mobile outdoors with two aids or a 
frame (Table III). There was no statistical evidence of a differ-
ence between treatment groups in the odds of declining functional 
mobility (adjusted odds ratio (OR) 0.991, 95% CI 0.748 to 1.313).
Less than 3% of participants receiving XHS (11/401) and SHS 
(13/493) reported any type of revision surgery during follow- up 
period (Table IV). There was no statistical evidence of a differ-
ence between treatment groups in the odds of requiring revision 
surgery in the 12- month post- intervention period (adjusted OR 
1.260; 95% CI 0.563 to 2.820); Table III). Overall complica-
tions were reasonably well balanced between treatment groups 
(SupplementaryTable v) and there was no statistical difference 
in the reporting of complications across the 12- month follow- up 
period (adjusted OR 0.936; 95% CI 0.784 to 1.117) or in the 
odds of dying (adjusted OR 0.873; 95% CI 0.647 to 1.176).
Discussion
The findings of this trial provide strong evidence that any difference 
in the HRQoL between patients treated with XHS or SHS at any 
timepoint in the year following hip fracture surgery is small and not 
clinically important. All sensitivity analyses of the primary outcome 
were concordant with the principal finding.
The finding of the primary analysis of HRQoL at four months 
was maintained at long- term follow- up at one year. Mortality, 
functional, and residential status outcomes were also not different 
between the treatment groups. There was no evidence of a differ-
ence in the overall safety profile of both treatments, with all- cause 
revision surgery risk and complication profiles that were similar. 
The findings of this definitive trial do not support the inferences of 
superiority of the XHS based upon the findings of earlier biome-
chanical and pilot clinical investigations.6-8
We observed a comparatively low risk of revision surgery, lower 
than reported in previous smaller studies.24 This may be associ-
ated with changes in co- interventions in clinical practice such as 
an increased prioritization of hip fracture surgery on operating lists 
or improved supervision of training surgeons associated with the 
implementation of best practice tariff.25 It is likely that the patients’ 
recovery following hip fracture is only moderately influenced by the 
selection of the surgical implant.
This was a large, pragmatic, multicentre, multisurgeon, random-
ized controlled trial. The strengths of this study are those inherent to 
the design—a randomized study nested within a cohort, a low risk 
of confounding, and findings that we believe to be generalizable. 
In addition, the sample was very large, including a wide variety of 
trochanteric fracture types and participants, attrition was relatively 
low given the population, and the outcomes measured were those 
most relevant to the patients and clinicians involved in their care.26
The attrition rate in the trial was anticipated but nevertheless 
considerable (13.1% at four months and 19.4% at 12 months) but 
this was reasonably balanced between groups and less than the 
planning assumptions reported in the protocol. Patients sustaining 
hip fracture are frail with a high mortality and often increase their 
level of care following the fracture. Approximately 10% of the 
participants allocated to the XHS did not receive this intervention; 
however, the primary ITT and sensitivity PP and CACE analyses 
produced similar findings. The revision risk was much lower than 
that reported most commonly in randomized and non- randomized 
comparative studies of extramedullary implants (e.g. XHS and 
SHS). We used a threefold approach to collecting these data—par-
ticipant/carer self- report, hospital medical records, and review of all 
participants’ available clinical imaging at 12 months. It is possible 
that participants underwent revision in hospitals outside of those 
included in the trial, although the vast majority of patients return to 
their index hospital if complications occur. It is also possible that this 
finding is due to potential centre effects, and hospitals participating 
in the trial may not reflect wider UK practice.
In conclusion we have found no evidence of any difference in 
HRQoL among patients with trochanteric hip fractures treated 
with either the XHS or SHS. This is despite biomechanical data to 
support the XHS and an indication of an improved revision risk in 
our previous pilot study.8
Take home message
  - There was no statistically significant difference in the health- 
related quality of life at four and 12 months between X- bolt 
Dynamic Plating System and the sliding hip screw.
  - The findings suggest no clinically meaningful difference between 
the novel and standard implants in the treatment of trochanteric hip 
fractures.
  - Revision surgery risks are low in UK practice; current national 
recommendations for surgical care of these fractures should remain 
unchanged.
Twitter
Follow X. L. Griffin @xlgriffin
  Animation
An animation is available alongside the online version 
of this article and at  vimeo. com/ 480824150.
Supplementary material
  A summary of each of the dimension scores of the five- 
level EuroQol Five- dimensions Health Status and 
Index provided by respondents and the prespecified 
sensitivity analyses which support the primary analysis.
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